Cannabis: A Potential Fountain of Youth for Your Body's Endocannabinoid System

Age differences in endocannabinoid tone are ameliorated after recent cannabis use.

Scientific reports • • Moderately Relevant
🤖

AI Summary

The human endocannabinoid system naturally changes as we age, with older adults typically showing reduced activity that may contribute to various health challenges. This groundbreaking study examined how cannabis use impacts endocannabinoid levels across different age groups, revealing fascinating insights into how the body responds to cannabinoids throughout life.

At baseline, researchers discovered significant differences in endocannabinoid levels between age groups, with older adults showing lower levels of key endocannabinoids like AEA and DEA compared to younger participants. Remarkably, acute cannabis consumption increased most endocannabinoid levels across all age groups, with particularly pronounced effects in older adults. The most dramatic changes were observed in AEA and DEA levels, suggesting that cannabis may help compensate for age-related declines in the endocannabinoid system.

These findings have profound implications for understanding how cannabis might support physiological balance as we age. By demonstrating that cannabis can uniformly elevate endocannabinoid levels, the study opens new avenues for exploring potential therapeutic applications for age-related conditions such as chronic pain and cognitive decline. The research highlights the complex and nuanced ways cannabis interacts with our body's natural biological systems.

📄 Original Abstract

An age-related decline in endocannabinoid system (ECS) activity may contribute to conditions such as chronic pain and Alzheimer's disease. Although cannabis is increasingly used by older adults to alleviate age-related conditions, it remains unclear how cannabinoids affect ECS activity across the lifespan. The present study assayed levels of seven endocannabinoids (AEA, 2-AG, DEA, LEA, PEA, SEA, and OEA) in a sample of adults (N = 142; younger 21-24 years, n = 38; midlife 25-54, n = 73; older 55-71, n = 31) assayed before cannabis use (baseline [pre-use]) and ~ 1 h after flower or ~ 2 h after edible cannabis use. At baseline, older adults exhibited lower AEA and DEA than younger adults, and lower LEA than midlife adults. Acute cannabis use increased AEA, DEA, LEA, PEA, SEA, and OEA across all age groups (all p < .001). 2-AG showed no increase. For AEA and DEA, increases were larger in older adults (Time×Age). These findings indicate broad endocannabinoid elevations after cannabis use regardless of age, alongside age-related differences at baseline and in acute responses.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.